ADAR1 Capital Management »

Vyne Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $338k 110k 3.07

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Vyne Therapeutics

Cormorant Asset Management
Eventide Asset Management
Citadel Advisors
DSC Advisors
Silverarc Capital Management
Palo Alto Investors
Vanguard Group
Exome Asset Management
Parkman Healthcare Partners
AlphaCentric Advisors
Schonfeld Strategic Advisors
Geode Capital Management
Renaissance Technologies
BlackRock
BlackRock

View all funds holding Vyne Therapeutics